Osiyan Bioscience Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 2.50 M
- Company Age 29 Year, 2 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 7.00 M
- Revenue Growth 19.84%
- Profit Growth 1.36%
- Ebitda 157.37%
- Net Worth 15.16%
- Total Assets -17.41%
About Osiyan Bioscience
Osiyan Bioscience Private Limited (OBPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 30 November 1995 and has a history of 29 years and two months. Its registered office is in Bangaluru, Karnataka, India.
The Corporate was formerly known as Answet India Private Limited. The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹7.00 M.
Savita and Kirthi Jain serve as directors at the Company.
Company Details
-
Location
Bangaluru, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U85110KA1995PTC019288
-
Company No.
019288
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
30 Nov 1995
-
Date of AGM
30 Nov 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Osiyan Bioscience?
Board Members (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Savita | Director | 30-Nov-2005 | Current |
Kirthi Jain | Director | 15-Jul-2015 | Current |
Financial Performance of Osiyan Bioscience.
Osiyan Bioscience Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 19.84% increase. The company also saw a slight improvement in profitability, with a 1.36% increase in profit. The company's net worth Soared by an impressive increase of 15.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Osiyan Bioscience?
In 2021, Osiyan Bioscience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹7.00 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.70 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
22 Oct 2022 | State Bank Of India | ₹7.00 M | Open |
How Many Employees Work at Osiyan Bioscience?
Unlock and access historical data on people associated with Osiyan Bioscience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Osiyan Bioscience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Osiyan Bioscience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.